Trial Profile
A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs STP 206 (Primary)
- Indications Acute enterocolitis; Necrotising enterocolitis
- Focus Adverse reactions
- Sponsors Leadiant Biosciences
- 23 Jan 2019 Status changed from recruiting to completed.
- 02 Apr 2015 According to Sigma-Tau Pharmaceuticals, STP-206 received Orphan Drug Designation in U.S.
- 09 Feb 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019 as reported by ClinicalTrials.gov record.